FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243190710> ?p ?o ?g. }

• W4243190710 endingPage "669" @default.
• W4243190710 startingPage "669.13" @default.
• W4243190710 abstract "<h3>Background</h3> F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to image synovial inflammation in patients with rheumatoid arthritis (RA). Tocilizumab (TCZ) binds soluble as well as membrane bound interleukin-6 (IL-6) receptors, hindering IL-6 from exerting its pro-inflammatory effects. After the initiation of the TCZ therapies, the serum CRP level and ESR are usually decreased, which lead to the difficulty of the evaluation of the treatment responses. <h3>Objectives</h3> One of the merits of PET is quantitative measurement of metabolic activity. Therefore, in this study, for the assessment of the activity of synovitis, we measured standardized uptake value (SUVs) of the affected joints at baseline and after treatment, compared them in themselves and with the clinical findings. In addition, we evaluated if FDG PET would be able to detect a clinical response in the individual joints of RA patients undergoing anti-IL-6 therapies. <h3>Methods</h3> FDG-PET and the clinical assessments were performed, at baseline (0M) and 3 months (3M) after the initiation of the TCZ therapies. The clinical assessment included ESR, CRP and MMP-3. Activity of inflammation was evaluated using DAS28-ESR(4), SDAI and CDAI. PET images were interpreted by experienced nuclear physician and increased FDG uptake in bilateral shoulder, elbow, wrist, hip, knee, and ankle joints were recorded. Therapeutic response was evaluated by the changes in the sum of the maximal SUV (SUVmax-sum) of all measured joints and the clinical findings. ΔSUV were defined as follows; ΔSUV=SUVmax-sum(0M) - SUVmax-sum(3M)_. In the following result section, Δ means the difference in the value between at baseline and after the treatment. <h3>Results</h3> Eleven (3 men, 8 women; average age: 60.3 (30-82) years) who underwent anti-IL-6 therapies were assessed. The average disease duration of these patients was 17.7 (2-52) years. At baseline, the average of the measured parameters were below; DAS28-ESR(4) 4.89±1.71 (2.49-8.88), SDAI 21.9±20.3 (3.21-75.1), CDAI 20.0±18.9 (2.80-68.0), ESR (mm/h) 70.5±33.7 (16-122), CRP (mg/dl) 1.90±2.02 (0.11-7.10), MMP-3 (ng/ml) 290.5±249.1(28.4-706.8), Tender joint count of 44 joints (TJC) 5.9±10.3 (0-36), Swollen joint count of 44 joints (SJC) 6.9±7.0 (1-24), SUVmax-sum 26.43±9.52 (18.78-53.61). After treatment, the average of observed value were below; DAS28-ESR(4) 2.94±1.56 (1.25-6.28), SDAI 9.1±12.0 (0.71-40.9), CDAI 9.0±11.5 (0.70-39.0), ESR (mm/h) 17.0±15.43 (5-55), CRP (mg/dl) 0.19±0.56 (0.01-1.90), MMP-3 (ng/ml) 139.0±184.1 (32.1-600.7), TJC 3.9±7.4 (0-25), SJC 3.2±5.0 (0-17), SUVmax-sum 21.42±6.98 (14.69-39.59). All disease parameters except for MMP-3 and TJC were significantly decreased after the TCZ treatment compared to the baseline (p<0.01). The ΔSUV significantly correlated with the ΔMMP-3 (r=0.655, p=0.029) and the ΔTJC (r=0.625, p=0.040). At baseline, there were 21 tender joints and 20 swollen joints of all the FDG-PET affected joints. The SUVmax of these joints were significantly decreased after 3M TCZ therapies (p<0.001). <h3>Conclusions</h3> The FDG-uptakes of the inflamed RA joints decreased 3 months after the initiation of TCZ treatment. TCZ might exert rapid effects on the synovitis of RA patietnts. FDG-PET can be used to evaluate the response of RA patients to the TCZ therapy. <h3>Disclosure of Interest</h3> None Declared" @default.
• W4243190710 created "2022-05-12" @default.
• W4243190710 creator A5003795361 @default.
• W4243190710 creator A5023243061 @default.
• W4243190710 creator A5029442889 @default.
• W4243190710 creator A5033185902 @default.
• W4243190710 creator A5036790549 @default.
• W4243190710 creator A5088371756 @default.
• W4243190710 date "2013-06-01" @default.
• W4243190710 modified "2023-10-14" @default.
• W4243190710 title "AB0548 The assessment of anti-IL-6 treatments in patients with rheumatoid arthritis using FDG-PET/CT" @default.
• W4243190710 doi "https://doi.org/10.1136/annrheumdis-2012-eular.548" @default.
• W4243190710 hasPublicationYear "2013" @default.
• W4243190710 type Work @default.
• W4243190710 citedByCount "0" @default.
• W4243190710 crossrefType "journal-article" @default.
• W4243190710 hasAuthorship W4243190710A5003795361 @default.
• W4243190710 hasAuthorship W4243190710A5023243061 @default.
• W4243190710 hasAuthorship W4243190710A5029442889 @default.
• W4243190710 hasAuthorship W4243190710A5033185902 @default.
• W4243190710 hasAuthorship W4243190710A5036790549 @default.
• W4243190710 hasAuthorship W4243190710A5088371756 @default.
• W4243190710 hasConcept C126322002 @default.
• W4243190710 hasConcept C142724271 @default.
• W4243190710 hasConcept C199374082 @default.
• W4243190710 hasConcept C2775842073 @default.
• W4243190710 hasConcept C2776914184 @default.
• W4243190710 hasConcept C2777178219 @default.
• W4243190710 hasConcept C2777575956 @default.
• W4243190710 hasConcept C2778640784 @default.
• W4243190710 hasConcept C2779244835 @default.
• W4243190710 hasConcept C2989005 @default.
• W4243190710 hasConcept C71924100 @default.
• W4243190710 hasConceptScore W4243190710C126322002 @default.
• W4243190710 hasConceptScore W4243190710C142724271 @default.
• W4243190710 hasConceptScore W4243190710C199374082 @default.
• W4243190710 hasConceptScore W4243190710C2775842073 @default.
• W4243190710 hasConceptScore W4243190710C2776914184 @default.
• W4243190710 hasConceptScore W4243190710C2777178219 @default.
• W4243190710 hasConceptScore W4243190710C2777575956 @default.
• W4243190710 hasConceptScore W4243190710C2778640784 @default.
• W4243190710 hasConceptScore W4243190710C2779244835 @default.
• W4243190710 hasConceptScore W4243190710C2989005 @default.
• W4243190710 hasConceptScore W4243190710C71924100 @default.
• W4243190710 hasIssue "Suppl 3" @default.
• W4243190710 hasLocation W42431907101 @default.
• W4243190710 hasOpenAccess W4243190710 @default.
• W4243190710 hasPrimaryLocation W42431907101 @default.
• W4243190710 hasRelatedWork W2037917858 @default.
• W4243190710 hasRelatedWork W2155028266 @default.
• W4243190710 hasRelatedWork W2324841173 @default.
• W4243190710 hasRelatedWork W2327734344 @default.
• W4243190710 hasRelatedWork W2416200202 @default.
• W4243190710 hasRelatedWork W2441992926 @default.
• W4243190710 hasRelatedWork W2603037975 @default.
• W4243190710 hasRelatedWork W3121700543 @default.
• W4243190710 hasRelatedWork W4242437488 @default.
• W4243190710 hasRelatedWork W2065293415 @default.
• W4243190710 hasVolume "71" @default.
• W4243190710 isParatext "false" @default.
• W4243190710 isRetracted "false" @default.
• W4243190710 workType "article" @default.